Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia, Ajax, and ...

This adjustment reflects the discontinuation of the belrestotug program, following disappointing trial results. Despite these setbacks, iTeos continues its research efforts, with ongoing studies such ...

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer. T-DXd plus pertuzumab improved PFS and DOR across ...